STORM Therapeutics

Executive Summary

STORM Therapeutics is a pioneering biotechnology company headquartered in Cambridge, UK, focused on the emerging field of RNA epigenetics. Founded in 2015, the company is developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer, leveraging a novel approach that targets the regulatory machinery of RNA to modulate gene expression and disrupt cancer cell growth. As a privately held firm currently in Phase 1 clinical development, STORM is advancing its lead candidate through early human trials, with a pipeline targeting undrugged RNA-modifying enzymes across multiple oncology indications. The company's platform holds promise for addressing a wide range of cancers by unlocking a new class of therapeutic targets distinct from conventional epigenetic modifiers. STORM's strategy builds on the growing recognition of RNA modifications—such as N6-methyladenosine (m6A)—as key drivers of tumorigenesis and drug resistance. By developing selective small molecule inhibitors, the company aims to provide differentiated treatments that complement existing immunotherapies and targeted agents. While still in early clinical stages, STORM's science has attracted attention from academic collaborators and investors. The company's near-term value hinges on successful Phase 1 data demonstrating safety, tolerability, and early signs of efficacy, as well as progression toward Phase 2 readiness. With a strong scientific foundation and a first-in-class approach, STORM represents a high-risk, high-reward opportunity in the precision oncology space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and pharmacokinetic data readout for lead candidate55% success
• Q4 2026IND filing for second pipeline candidate targeting a novel RNA-modifying enzyme40% success
• Q1 2027Potential partnership or licensing deal for co-development of lead program30% success